Huatai Bairui Fund Management Co. Ltd. - CSI Shanghai Hong Kong Shenzhen Innovative Drug ETF (SHA:517120)

Assets	n/a
Expense Ratio	0.60%
PE Ratio	n/a
Dividend (ttm)	n/a
Dividend Yield	n/a
Ex-Dividend Date	n/a
Payout Frequency	n/a
Payout Ratio	n/a
1-Year Return	-1.26%

Volume	13,546,200
Open	0.7820
Previous Close	0.7820
Day's Range	0.7790 - 0.7910
52-Week Low	0.5670
52-Week High	0.8170
Beta	0.40
Holdings	78
Inception Date	Jul 8, 2021

About 517120

517120.SS was created on 2021-07-08 by Huatai. The fund's investment portfolio concentrates primarily on health care equity. The index of the target is closely tracked, and the tracking deviation and tracking error are minimized

• Asset Class: Equity
• Category: Health Care
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 517120
• Provider: Huatai
• Index Tracked: China Securities Shanghai-Hong Kong-Shenzhen Innovative Medicine Industry Index

Performance

517120 had a total return of -1.26% in the past year, including dividends. Since the fund's inception, the average annual return has been -4.53%.

Top 10 Holdings

61.79% of assets

Name	Symbol	Weight
WuXi AppTec Co., Ltd.	603259	11.41%
Jiangsu Hengrui Pharmaceuticals Co.,Ltd	600276	10.00%
BeOne Medicines AG	6160	9.24%
WuXi Biologics (Cayman) Inc.	2269	6.90%
Innovent Biologics, Inc.	1801	6.76%
Cash	n/a	4.83%
WuXi AppTec Co., Ltd.	2359	3.71%
Akeso, Inc.	9926	3.47%
Hansoh Pharmaceutical Group Company Limited	3692	2.76%
CSPC Pharmaceutical Group Limited	1093	2.72%

Data Sources: S&P Global Market Intelligence and Finnhub

Historical data is provided by S&P Global Market Intelligence. Several fund data points are also provided by Finnhub.

Last checked:

Sep 23, 2026

Data Sources Report a data error